BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants

Phase 1

Completed

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Rosuvastatin

First Posted Date: 2021-05-17

Last Posted Date: 2023-08-09

Lead Sponsor: Bayer

Target Recruit Count: 16

Registration Number: NCT04889287

Locations: 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany

A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Phase 1

Completed

Conditions: Diabetic Nephropathy
Worsening Chronic Heart Failure

Interventions: Drug: Finerenone (BAY94-8862)

First Posted Date: 2021-05-11

Last Posted Date: 2021-07-16

Lead Sponsor: Bayer

Target Recruit Count: 27

Registration Number: NCT04881994

A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose

Phase 1

Completed

Conditions: Obstructive Sleep Apnea

Interventions: Drug: BAY2586116
Drug: Placebo

First Posted Date: 2021-05-04

Last Posted Date: 2023-03-01

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT04872387

Locations: 🇯🇵
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan

A Trial to Learn What Happens to Different Medicinal Forms of BAY2328065 When They Enter the Body and How Safe They Are in Healthy Male and Female Participants

Phase 1

Completed

Conditions: Endometriosis

Interventions: Drug: BAY2328065
Drug: Placebo

First Posted Date: 2021-04-20

Last Posted Date: 2022-06-01

Lead Sponsor: Bayer

Target Recruit Count: 31

Registration Number: NCT04851483

Locations: 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany

COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older

Phase 3

Withdrawn

Conditions: SARS-CoV-2 Infection
Coronavirus Disease 2019 (COVID-19)

Interventions: Biological: SARS-CoV-2 mRNA Vaccine (CVnCoV)
Biological: Quadrivalent influenza vaccine (QIV)
Other: Placebo

First Posted Date: 2021-04-19

Last Posted Date: 2021-08-11

Lead Sponsor: Bayer

Registration Number: NCT04848467

Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

Phase 1

Completed

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Interventions: Drug: Elinzanetant (BAY3427080) treatment A
Drug: Elinzanetant (BAY3427080) treatment B

First Posted Date: 2021-04-15

Last Posted Date: 2023-08-09

Lead Sponsor: Bayer

Target Recruit Count: 16

Registration Number: NCT04845841

Locations: 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany

A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients

Completed

Conditions: Peripheral Artery Disease

Interventions: Procedure: Lower limb revascularization

First Posted Date: 2021-04-01

Last Posted Date: 2022-04-25

Lead Sponsor: Bayer

Target Recruit Count: 227613

Registration Number: NCT04824729

Locations: 🇫🇷
PMSI, Multiple Locations, France

Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment

Phase 1

Terminated

Conditions: Chronic Kidney Disease

Interventions: Drug: Runcaciguat (BAY1101042)

First Posted Date: 2021-03-29

Last Posted Date: 2021-07-15

Lead Sponsor: Bayer

Target Recruit Count: 5

Registration Number: NCT04820621

Locations: 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

Active, not recruiting

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Riociguat (Adempas, BAY63-2521)

First Posted Date: 2021-03-24

Last Posted Date: 2024-12-16

Lead Sponsor: Bayer

Target Recruit Count: 500

Registration Number: NCT04813926

Locations: 🇺🇸
Cedar Sinai, Los Angeles, California, United States
🇺🇸
Northwestern, Chicago, Illinois, United States
🇺🇸
UCSF, Fresno, California, United States

and more 47 locations

A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer

Phase 1

Terminated

Conditions: Metastatic Melanoma and Other Solid Tumors

Interventions: Drug: BAY2666605

First Posted Date: 2021-03-22

Last Posted Date: 2023-12-14

Lead Sponsor: Bayer

Target Recruit Count: 5

Registration Number: NCT04809805

Locations: 🇺🇸
Sarah Cannon Development Innovations, Nashville, Tennessee, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
South Texas Accelerated Research Therapeutics | START San Antonio, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy